More Ranbaxy woes

Share this article:

The FDA has put Ranbaxy Laboratories on notice.

Again.

Bloomberg reports that the US regulator says a recent inspection shows a Punjab, India, plant that makes 60% to 70% of the company's active ingredients is failing to make the grade.

The company agreed to shell out $500 million over fraud allegations in May, and Bloomberg notes that the US has already banned items from three Ranbaxy plants from entering the country.

Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Channel

This compelling e-book shares a wealth of insights designed to help members of sales forces connect with elusive HCPs. An expanded version has also been created that includes video interviews and other multimedia content. Click here for access.